ALK and anaplastic large cell lymphoma: Collectively, our findings suggest that the epigenetic profiling or expression analysis of miR-125b in NPM-ALK(+) ALCL could be used as a resistance marker/target to predict therapeutic outcome and improve the response of cells resistant to doxorubicin.